Seres Therapeutics Company Profile (NASDAQ:MCRB)

About Seres Therapeutics

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MCRB
  • CUSIP:
Key Metrics:
  • Previous Close: $9.19
  • 50 Day Moving Average: $10.04
  • 200 Day Moving Average: $10.85
  • 52-Week Range: $8.05 - $35.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.34
  • P/E Growth: -0.08
  • Market Cap: $370.86M
  • Outstanding Shares: 40,355,000
  • Beta: 0.3
Profitability:
  • Return on Equity: -47.97%
  • Return on Assets: -30.02%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 6.54%
  • Quick Ratio: 6.54%
Additional Links:
Companies Related to Seres Therapeutics:

Analyst Ratings

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $26.17 (184.73% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017Cowen and CompanyReiterated RatingBuyView Rating Details
1/31/2017Cantor FitzgeraldSet Price TargetBuy$16.00View Rating Details
2/1/2017FBR & CoLower Price TargetOutperform$23.00 -> $18.00View Rating Details
1/31/2017Canaccord GenuityReiterated RatingBuy$20.00View Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details
8/1/2016Bank of America CorpDowngradeBuy -> NeutralView Rating Details
7/29/2016HC WainwrightInitiated CoverageBuy$50.00View Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$35.00 -> $34.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Seres Therapeutics (NASDAQ:MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
2/23/2017Q4 2016($0.72)N/AView Earnings Details
11/10/2016Q316($0.50)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
Current Year EPS Consensus Estimate: $-2.40 EPS
Next Year EPS Consensus Estimate: $-2.75 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.54)($0.54)($0.54)
Q2 20162($0.62)($0.24)($0.43)
Q3 20162($0.49)($0.20)($0.35)
Q4 20162($0.77)($0.67)($0.72)
Q1 20172($0.73)($0.56)($0.65)
Q2 20172($0.59)($0.50)($0.55)
Q3 20172($0.74)($0.61)($0.68)
Q4 20172($0.75)($0.63)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Seres Therapeutics (NASDAQ:MCRB)
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 77.62%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
DateHeadline
News IconSeres Therapeutics Inc MCRB Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:MCRB)
www.bioportfolio.com - February 23 at 6:29 PM
News IconMomentum Watch on Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Midway Monitor (NASDAQ:MCRB)
midwaymonitor.com - February 22 at 11:39 PM
News IconMomentum Watch on Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - BVN (NASDAQ:MCRB)
bvnewsjournal.com - February 17 at 2:25 PM
News IconAverage Directional Index Review for Seres Therapeutics Inc. (MCRB) - BVN (NASDAQ:MCRB)
bvnewsjournal.com - February 15 at 6:01 AM
finance.yahoo.com logoSeres Therapeutics Announces Participation at Two Upcoming Investor Conferences (NASDAQ:MCRB)
finance.yahoo.com - February 3 at 7:10 PM
streetinsider.com logoSeres Therapeutics (MCRB) Reports Key Findings from SER-109 ... - StreetInsider.com (NASDAQ:MCRB)
www.streetinsider.com - February 2 at 7:18 PM
News IconSeres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA - Xconomy (NASDAQ:MCRB)
www.xconomy.com - February 2 at 5:35 AM
biz.yahoo.com logoSeres Therapeutics Inc Conference Call to Discuss Key Findings from SER-109 Phase 2 Study Analyses scheduled for 8:00 am ET today (NASDAQ:MCRB)
us.rd.yahoo.com - February 1 at 5:20 AM
streetinsider.com logoSeres Therapeutics (MCRB) Reports Key Findings from SER-109 Phase 2 Study Analyses (NASDAQ:MCRB)
www.streetinsider.com - January 31 at 7:20 PM
us.rd.yahoo.com logoSeres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses (NASDAQ:MCRB)
us.rd.yahoo.com - January 31 at 7:20 PM
us.rd.yahoo.com logo7:01 am Seres Therapeutics announces key findings from SER-109 Phase 2 Study analyses; findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patient (NASDAQ:MCRB)
us.rd.yahoo.com - January 31 at 7:20 PM
biz.yahoo.com logoCoty Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:MCRB)
biz.yahoo.com - January 31 at 7:20 PM
bizjournals.com logoSeres finally explains 'poop pill' failure, reassuring investors (NASDAQ:MCRB)
www.bizjournals.com - January 31 at 7:20 PM
businesswire.com logoSeres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study ... - Business Wire (press release) (NASDAQ:MCRB)
www.businesswire.com - January 30 at 7:08 PM
finance.yahoo.com logoSeres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses (NASDAQ:MCRB)
finance.yahoo.com - January 30 at 7:08 PM
finance.yahoo.com logo4:01 pm Seres Therapeutics will host call on Jan 31 at 8am ET to discuss results of in-depth analyses of previously reported SER-109 Ph 2 clinical study in patients with multiply recurrent C. difficile infection (NASDAQ:MCRB)
finance.yahoo.com - January 30 at 7:08 PM
News IconMarket Focus - Tracking These Shares: Seres Therapeutics, Inc. (NASDAQ:MCRB) - Gilbert Daily (NASDAQ:MCRB)
gilbertdaily.com - January 30 at 9:54 AM
News IconTechnical Indicator Review on Shares of Seres Therapeutics Inc. (MCRB) - Sherwood Daily (NASDAQ:MCRB)
sherwooddaily.com - January 24 at 7:13 PM
News IconEarnings in Full Force, Analysts Take Aim at Seres Therapeutics Inc (NASDAQ:MCRB) - Wall Street Beacon (NASDAQ:MCRB)
wsbeacon.com - January 24 at 7:13 PM
News IconHow Will We Stop the Rise of Superbugs? (NASDAQ:MCRB)
www.wallstreetdaily.com - January 19 at 8:28 PM
capitalcube.com logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : January 18, 2017 (NASDAQ:MCRB)
www.capitalcube.com - January 18 at 6:59 PM
News IconSeres Therapeutics, Inc. (MCRB) Shares Active after Upgrade at ... - BNB Daily (blog) (NASDAQ:MCRB)
www.baseball-news-blog.com - January 17 at 6:50 PM
News IconSeres Therapeutics Inc MCRB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MCRB)
www.bioportfolio.com - January 7 at 8:48 PM
capitalcube.com logoSeres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : January 6, 2017 (NASDAQ:MCRB)
www.capitalcube.com - January 6 at 7:07 PM
capitalcube.com logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : January 5, 2017 (NASDAQ:MCRB)
www.capitalcube.com - January 5 at 7:53 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Seres Therapeutics, Inc. (NASDAQ:MCRB) - Prospect Journal (NASDAQ:MCRB)
prospectjournal.com - January 3 at 10:57 AM
thestreet.com logoCommit To Purchase Seres Therapeutics At $7.50, Earn 19.6% Annualized Using Options - TheStreet.com (NASDAQ:MCRB)
www.thestreet.com - December 22 at 6:45 PM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Initiates Coverage On Seres Therapeutics (NASDAQ:MCRB) With a Overweight (NASDAQ:MCRB)
marketexclusive.com - December 17 at 12:06 AM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Initiates Coverage On Seres ... - Market Exclusive (NASDAQ:MCRB)
marketexclusive.com - December 16 at 7:05 PM
4-traders.com logoFlagship Ventures : Evolves Name To Flagship Pioneering (NASDAQ:MCRB)
www.4-traders.com - December 15 at 12:21 AM
finance.yahoo.com logoFlagship Ventures Evolves Name To Flagship Pioneering (NASDAQ:MCRB)
finance.yahoo.com - December 15 at 12:21 AM
insidermonkey.com logoIs Seres Therapeutics Inc (MCRB) A Good Stock To Buy? (NASDAQ:MCRB)
www.insidermonkey.com - December 14 at 7:09 PM
News IconTraders are Keeping Track of Technicals on Shares of Seres Therapeutics Inc. (MCRB) - Yankee Analysts (NASDAQ:MCRB)
yankeeanalysts.com - December 10 at 5:54 PM
News IconTechnical Study: Following Indicators for Seres Therapeutics Inc. (MCRB) - Yankee Analysts (NASDAQ:MCRB)
yankeeanalysts.com - December 10 at 5:54 PM
globenewswire.com logoDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of a Class Action Lawsuit ... - GlobeNewswire (press release) (NASDAQ:MCRB)
globenewswire.com - November 29 at 2:56 PM
finance.yahoo.com logoDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2016 – MCRB (NASDAQ:MCRB)
finance.yahoo.com - November 29 at 2:56 PM
finance.yahoo.com logoMONDAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm (NASDAQ:MCRB)
finance.yahoo.com - November 25 at 11:20 AM
News IconCompany Focus: Zooming in on Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - The Business Journal (NASDAQ:MCRB)
belmontbusinessjournal.com - November 24 at 6:09 PM
baystreet.ca logoBy: Baystreet Staff - Tuesday, November 22, 2016 - Baystreet.ca (NASDAQ:MCRB)
www.baystreet.ca - November 24 at 6:09 PM
businesswire.com logoMCRB LOSS ALERT Rosen Law Firm Reminds Seres Therapeutics, Inc. Investors of Important November 28 Deadline ... - Business Wire (press release) (NASDAQ:MCRB)
www.businesswire.com - November 24 at 6:09 PM
News IconDeadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming November 28 Deadline in the Class Action Law... (NASDAQ:MCRB)
ih.advfn.com - November 23 at 6:07 PM
finance.yahoo.com logoMCRB LOSS ALERT Rosen Law Firm Reminds Seres Therapeutics, Inc. Investors of Important November 28 Deadline in Lawsuit - MCRB (NASDAQ:MCRB)
finance.yahoo.com - November 23 at 6:07 PM
finance.yahoo.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2016 (NASDAQ:MCRB)
finance.yahoo.com - November 23 at 6:07 PM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seres Therapeutics, Inc. (MCRB) & Lead Plaintiff Deadline: November 28, 2016 (NASDAQ:MCRB)
finance.yahoo.com - November 23 at 6:07 PM
finance.yahoo.com logo5-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:MCRB)
finance.yahoo.com - November 23 at 6:07 PM
finance.yahoo.com logoDeadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming November 28 Deadline in the Class Action Lawsuit Against Seres Therapeutics, Inc. (NASDAQ:MCRB)
finance.yahoo.com - November 23 at 6:07 PM
4-traders.com logoSeres Therapeutics : Biotech Stocks Under Scanner -- PTC Therapeutics, Arena Pharma, BioDelivery Sciences, and Seres Therapeutics (NASDAQ:MCRB)
www.4-traders.com - November 23 at 9:12 AM
News IconDEADLINE ALERT Bronstein Gewirtz Grossman LLC Reminds Investors of Class Action Against Seres Therapeutics ... - EconoTimes (NASDAQ:MCRB)
www.econotimes.com - November 22 at 6:11 PM
News IconWhat is the Sell-side Saying About Seres Therapeutics Inc (NASDAQ:MCRB)? - CSZ News (NASDAQ:MCRB)
cincysportszone.com - November 22 at 6:11 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seres Therapeutics, Inc. (MCRB) & Lead Plaintiff Deadline: November 29, 2016 (NASDAQ:MCRB)
finance.yahoo.com - November 22 at 6:11 PM

Social

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?

8 equities research analysts have issued 12-month target prices for Seres Therapeutics' shares. Their forecasts range from $12.00 to $50.00. On average, they expect Seres Therapeutics' stock price to reach $26.17 in the next twelve months.

When will Seres Therapeutics announce their earnings?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/2/2017)

  • Cowen and Company analysts commented, "MCRB released root cause analysis findings from the SER-109 failed Ph2 and in-." (2/1/2017)

  • Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Who owns Seres Therapeutics stock?

Seres Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Federated Investors Inc. PA (2.76%), Artal Group S.A. (1.73%), ARK Investment Management LLC (1.22%), Renaissance Technologies LLC (0.99%) and State Street Corp (0.68%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship.

Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Tudor Investment Corp Et Al. Company insiders that have sold Seres Therapeutics stock in the last year include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship.

Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?

Seres Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Artal Group S.A., Renaissance Technologies LLC, Oxford Asset Management, State Street Corp, Trexquant Investment LP, FMR LLC and Ellington Management Group LLC.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Seres Therapeutics stock cost?

One share of Seres Therapeutics stock can currently be purchased for approximately $9.19.

Seres Therapeutics (NASDAQ:MCRB) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Earnings History Chart

Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Dividend History Chart

Dividend Payments by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Last Updated on 2/23/2017 by MarketBeat.com Staff